LLY - Eli Lilly marks gene editing foray in deal with Beam
2023-10-31 06:38:32 ET
More on Beam, Eli Lilly, etc.
- Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore
- Beam: Opportunity Based On SCD Data Readout In 2024
- Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
- Eli Lilly wins approval of first-in-class ulcerative colitis drug Omvoh
- Editas upgraded at Citi ahead of FDA AdCom on gene editing therapy
For further details see:
Eli Lilly marks gene editing foray in deal with Beam